早期海马萎缩是临床医生的重要信号,但未必是阿尔茨海默病的先兆
Early Hippocampal Atrophy Is an Important Signal for Clinicians but Not Necessarily a Harbinger of Alzheimer Disease.
PubMed 文献 · Neurology · 2023-11-08
本文指出痴呆是当今最严峻的医疗挑战之一,抗β-淀粉样蛋白(Aβ)疗法有望延缓阿尔茨海默病(AD)进展,但远非治愈手段,且混杂病理过程与混合疾病状态等挑战仍存,这些挑战在生前生物标志物应用方面才刚刚开始被应对。
要点
- 抗Aβ疗法有望延缓AD进展,但远非治愈手段。
- 混杂病理过程与混合疾病状态是当前面临的挑战。
- 生前生物标志物应用方面的挑战才刚刚开始被应对。
核心结论
- 早期海马萎缩是临床医生的重要信号,但未必是阿尔茨海默病的先兆。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Dementia is one of the most formidable health care challenges we face today. Fortunately, there is new hope for patients and clinicians because we are on the verge of anti-β-amyloid (Aβ) therapies to slow disease progression in Alzheimer disease (AD). But these new therapies are far from curative, and many challenges remain related to confounding pathologic processes and mixed disease states. These challenges are only beginning to be addressed in regard to the use of antemortem biomarkers.
来源:Neurology,查看原文。版权归原作者所有。
引用
- Nelson PT, Jicha GA. Early Hippocampal Atrophy Is an Important Signal for Clinicians but Not Necessarily a Harbinger of Alzheimer Disease. Neurology. 2023. PMID: 37968129. doi:10.1212/WNL.0000000000208071
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。